Literature DB >> 23439459

Severe hemorrhagic coagulopathy with hemophagocytic lymphohistiocytosis secondary to Epstein-Barr virus-associated T-cell lymphoproliferative disorder.

Pooja A Nawathe1, Thyyar M Ravindranath, Prakash Satwani, J Scott Baird.   

Abstract

OBJECTIVE: We describe the coagulopathy and hemorrhagic complications associated with fulminant, secondary hemophagocytic lymphohistiocytosis in a cohort of patients with Epstein-Barr virus-associated T-cell lymphoproliferative disorder. PATIENTS AND METHODS: Institutional Review Board-approved retrospective review of all patients at our children's hospital over 3 years (2008-2010) with hemophagocytic lymphohistiocytosis secondary to acute Epstein-Barr virus-associated T-cell lymphoproliferative disorder.
RESULTS: Four males (2, 3, 17, and 20 yr old) presented with fever, hepatosplenomegaly, and pancytopenia with elevated serum ferritin, and all met clinical and laboratory criteria for secondary hemophagocytic lymphohistiocytosis. d-dimer on admission was elevated in all patients and remained extremely elevated during hospitalization, while the median prothrombin and activated partial thromboplastin times as well as fibrinogen were all in the normal range. Within a few weeks to months following admission, all patients developed multiorgan system failure with episodes of severe, life-threatening hemorrhage; in all four patients, hemorrhage was not associated with a nadir in platelet count. There were no survivors beyond 4 months from diagnosis.
CONCLUSIONS: A coagulopathy characterized by persistent, extreme elevations in plasma d-dimer and severe, life-threatening hemorrhage was noted in association with hemophagocytic lymphohistiocytosis secondary to Epstein-Barr virus-associated T-cell lymphoproliferative disorder. We speculate that this coagulopathy is a marker of severe hemophagocytic lymphohistiocytosis in this setting.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23439459     DOI: 10.1097/PCC.0b013e3182720f94

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  3 in total

1.  The Treatment Effect of Protamine on Severe Coagulopathy in Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis: Case Reports and Literature Review.

Authors:  Qian Zhang; CunLiang Yan; Lei Xu; Wenyue Xie; JinMeng Li; Wenli Zhang; HaiChan Xu; HongYu Zhang
Journal:  Indian J Hematol Blood Transfus       Date:  2020-08-12       Impact factor: 0.900

2.  Computational discovery of Epstein-Barr virus targeted human genes and signalling pathways.

Authors:  Suyu Mei; Kun Zhang
Journal:  Sci Rep       Date:  2016-07-29       Impact factor: 4.379

3.  Coagulation Disorders and Bleedings in Critically Ill Patients With Hemophagocytic Lymphohistiocytosis.

Authors:  Sandrine Valade; Elie Azoulay; Lionel Galicier; David Boutboul; Lara Zafrani; Alain Stepanian; Emmanuel Canet; Virginie Lemiale; Marion Venot; Agnès Veyradier; Eric Mariotte
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.